Your browser doesn't support javascript.
loading
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson, John A; Schneider, Bryan J; Brahmer, Julie; Achufusi, Amaka; Armand, Philippe; Berkenstock, Meghan K; Bhatia, Shailender; Budde, Lihua E; Chokshi, Saurin; Davies, Marianne; Elshoury, Amro; Gesthalter, Yaron; Hegde, Aparna; Jain, Michael; Kaffenberger, Benjamin H; Lechner, Melissa G; Li, Tianhong; Marr, Alissa; McGettigan, Suzanne; McPherson, Jordan; Medina, Theresa; Mohindra, Nisha A; Olszanski, Anthony J; Oluwole, Olalekan; Patel, Sandip P; Patil, Pradnya; Reddy, Sunil; Ryder, Mabel; Santomasso, Bianca; Shofer, Scott; Sosman, Jeffrey A; Wang, Yinghong; Zaha, Vlad G; Lyons, Megan; Dwyer, Mary; Hang, Lisa.
Afiliação
  • Thompson JA; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
  • Schneider BJ; University of Michigan Rogel Cancer Center.
  • Brahmer J; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Achufusi A; University of Wisconsin Carbone Cancer Center.
  • Armand P; Dana-Farber/Brigham and Women's Cancer Center.
  • Berkenstock MK; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Bhatia S; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
  • Budde LE; City of Hope National Medical Center.
  • Chokshi S; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center.
  • Davies M; Yale Cancer Center/Smilow Cancer Hospital.
  • Elshoury A; Roswell Park Comprehensive Cancer Center.
  • Gesthalter Y; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Hegde A; O'Neal Comprehensive Cancer Center at UAB.
  • Jain M; Moffitt Cancer Center.
  • Kaffenberger BH; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Lechner MG; UCLA Jonsson Comprehensive Cancer Center.
  • Li T; UC Davis Comprehensive Cancer Center.
  • Marr A; Fred & Pamela Buffett Cancer Center.
  • McGettigan S; Abramson Cancer Center at the University of Pennsylvania.
  • McPherson J; Huntsman Cancer Institute at the University of Utah.
  • Medina T; University of Colorado Cancer Center.
  • Mohindra NA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Olszanski AJ; Fox Chase Cancer Center.
  • Oluwole O; Vanderbilt-Ingram Cancer Center.
  • Patel SP; UC San Diego Moores Cancer Center.
  • Patil P; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Reddy S; Stanford Cancer Institute.
  • Ryder M; Mayo Clinic Cancer Center.
  • Santomasso B; Memorial Sloan Kettering Cancer Center.
  • Shofer S; Duke Cancer Institute.
  • Sosman JA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Wang Y; The University of Texas MD Anderson Cancer Center.
  • Zaha VG; UT Southwestern Simmons Comprehensive Cancer Center; and.
  • Lyons M; National Comprehensive Cancer Network.
  • Dwyer M; National Comprehensive Cancer Network.
  • Hang L; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 20(4): 387-405, 2022 04.
Article em En | MEDLINE | ID: mdl-35390769
ABSTRACT
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncologia / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: J Natl Compr Canc Netw Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oncologia / Neoplasias Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: J Natl Compr Canc Netw Ano de publicação: 2022 Tipo de documento: Article